Expert Commentary

In the latest report from the WHI, the data contradict the conclusions

Author and Disclosure Information

 

References

Related Article: Update: Menopause Andrew M. Kaunitz, MD (May 2010)

THE BOTTOM LINE
We need to look at the totality of the data on menopausal HT, evaluate our patients individually, treat those who are truly hormonally deficient and suffering, and counsel them that many of the harms linked to HT have been exaggerated.

The pendulum is finally swinging back toward a more balanced assessment of the benefits and risks of HT, indicating that it may be appropriate for primary prevention of cardiovascular disease, osteoporosis, and type 2 diabetes—and thus can potentially expand the lifespan. It’s up to us to communicate this fact to our patients.

TELL US WHAT YOU THINK!
Share your thoughts on this article or on any topic relevant to ObGyns and women’s health practitioners. Tell us which topics you’d like to see covered in future issues, and what challenges you face in daily practice.
We will consider publishing your letter and in a future issue.
Send your letter to: obg@frontlinemedcom.com
Please include the city and state in which you practice.
Stay in touch! Your feedback is important to us!

Pages

Recommended Reading

STOP enforcing a 5-year rule for menopausal hormone therapy
MDedge ObGyn
FDA rejects flibanserin for low libido in women
MDedge ObGyn
No survival benefit to bisphosphonate in chemoresistant breast cancer
MDedge ObGyn
Is one oral estrogen formulation safer than another for menopausal women?
MDedge ObGyn
Don't tell patients estrogens are "bad"
MDedge ObGyn
When should a menopausal woman discontinue hormone therapy?
MDedge ObGyn
Romosozumab boosts bone density while cutting resorption
MDedge ObGyn
New stroke guidelines focus on women’s risks
MDedge ObGyn
VIDEO: Moderate exercise reduced women’s stroke risk
MDedge ObGyn
Moderate exercise reduces female stroke risk
MDedge ObGyn

Related Articles